Canaccord Genuity Reaffirms Hold Rating on XOMA Ltd (XOMA)

By admin | 6 years ago

XOMA Ltd (NASDAQ: XOMA)‘s stock had its “hold” rating reaffirmed by Canaccord Genuity in a research note issued on Monday.

Other equities research analysts have also recently issued reports about the stock. Analysts at Cowen initiated coverage on shares of XOMA Ltd in a research note to investors on Monday. They set an “outperform” rating on the stock. Separately, analysts at Cowen & Co initiated coverage on shares of XOMA Ltd in a research note to investors on Monday. They set an “outperform” rating on the stock. Finally, analysts at Ladenburg Thalmann cut their price target on shares of XOMA Ltd from $9.00 to $4.50 in a research note to investors on Tuesday, March 20th. They now have a “buy” rating on the stock.

XOMA Ltd opened at 2.59 on Monday. XOMA Ltd has a 52-week low of $1.04 and a 52-week high of $3.15. The company’s market cap is $176.3 million.

XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases.

About the author